Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences - PubMed (original) (raw)
Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences
C Sachse et al. Am J Hum Genet. 1997 Feb.
Abstract
Cytochrome P450 2D6 (CYP2D6) metabolizes many important drugs. CYP2D6 activity ranges from complete deficiency to ultrafast metabolism, depending on at least 16 different known alleles. Their frequencies were determined in 589 unrelated German volunteers and correlated with enzyme activity measured by phenotyping with dextromethorphan or debrisoquine. For genotyping, nested PCR-RFLP tests from a PCR amplificate of the entire CYP2D6 gene were developed. The frequency of the CYP2D6*1 allele coding for extensive metabolizer (EM) phenotype was .364. The alleles coding for slightly (CYP2D6*2) or moderately (*9 and *10) reduced activity (intermediate metabolizer phenotype [IM]) showed frequencies of .324, .018, and .015, respectively. By use of novel PCR tests for discrimination, CYP2D6 gene duplication alleles were found with frequencies of .005 (*1x2), .013 (*2x2), and .001 (*4x2). Frequencies of alleles with complete deficiency (poor metabolizer phenotype [PM]) were .207 (*4), .020 (*3 and *5), .009 (*6), and .001 (*7, *15, and *16). The defective CYP2D6 alleles *8, *11, *12, *13, and *14 were not found. All 41 PMs (7.0%) in this sample were explained by five mutations detected by four PCR-RFLP tests, which may suffice, together with the gene duplication test, for clinical prediction of CYP2D6 capacity. Three novel variants of known CYP2D6 alleles were discovered: *1C (T1957C), *2B (additional C2558T), and *4E (additional C2938T). Analysis of variance showed significant differences in enzymatic activity measured by the dextromethorphan metabolic ratio (MR) between carriers of EM/PM (mean MR = .006) and IM/PM (mean MR = .014) alleles and between carriers of one (mean MR = .009) and two (mean MR = .003) functional alleles. The results of this study provide a solid basis for prediction of CYP2D6 capacity, as required in drug research and routine drug treatment.
Comment in
- Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist?
Nebert DW. Nebert DW. Am J Hum Genet. 1997 Feb;60(2):265-71. Am J Hum Genet. 1997. PMID: 9012398 Free PMC article. Review. No abstract available.
Similar articles
- Phenotype and genotype analysis of debrisoquine hydroxylase (CYP2D6) in a black Zimbabwean population. Reduced enzyme activity and evaluation of metabolic correlation of CYP2D6 probe drugs.
Masimirembwa C, Hasler J, Bertilssons L, Johansson I, Ekberg O, Ingelman-Sundberg M. Masimirembwa C, et al. Eur J Clin Pharmacol. 1996;51(2):117-22. doi: 10.1007/s002280050170. Eur J Clin Pharmacol. 1996. PMID: 8911874 - Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population.
Broly F, Gaedigk A, Heim M, Eichelbaum M, Morike K, Meyer UA. Broly F, et al. DNA Cell Biol. 1991 Oct;10(8):545-58. doi: 10.1089/dna.1991.10.545. DNA Cell Biol. 1991. PMID: 1681816 - Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.
Zhou SF. Zhou SF. Clin Pharmacokinet. 2009;48(11):689-723. doi: 10.2165/11318030-000000000-00000. Clin Pharmacokinet. 2009. PMID: 19817501 Review. - Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry.
Zanger UM, Raimundo S, Eichelbaum M. Zanger UM, et al. Naunyn Schmiedebergs Arch Pharmacol. 2004 Jan;369(1):23-37. doi: 10.1007/s00210-003-0832-2. Epub 2003 Nov 15. Naunyn Schmiedebergs Arch Pharmacol. 2004. PMID: 14618296 Review.
Cited by
- Associations between Selected ADRB1 and CYP2D6 Gene Polymorphisms in Children with Ventricular and Supraventricular Arrhythmias.
Moric-Janiszewska E, Smolik S, Szydłowski L, Kapral M. Moric-Janiszewska E, et al. Medicina (Kaunas). 2023 Nov 21;59(12):2057. doi: 10.3390/medicina59122057. Medicina (Kaunas). 2023. PMID: 38138160 Free PMC article. - Genotype-guided new approach for dose optimisation of hydroxychloroquine administration in Chinese patients with SLE.
Xie H, Wen X, Wang Y, Huang X, Shu Q, Wang D, Geng L, Jin Z, Shen W, Ge W, Zhu Y, Sun L. Xie H, et al. Lupus Sci Med. 2023 Nov 22;10(2):e000997. doi: 10.1136/lupus-2023-000997. Lupus Sci Med. 2023. PMID: 37993281 Free PMC article. - The Impact of the CYP2D6 and CYP1A2 Gene Polymorphisms on Response to Duloxetine in Patients with Major Depression.
Maciaszek J, Pawłowski T, Hadryś T, Machowska M, Wiela-Hojeńska A, Misiak B. Maciaszek J, et al. Int J Mol Sci. 2023 Aug 30;24(17):13459. doi: 10.3390/ijms241713459. Int J Mol Sci. 2023. PMID: 37686266 Free PMC article. - Nonadherence by Serum Drug Analyses in Resistant Hypertension: 7-Year Follow-Up of Patients Considered Adherent by Directly Observed Therapy.
Halvorsen LV, Bergland OU, Søraas CL, Larstorp ACK, Hjørnholm U, Kjær VN, Kringen MK, Clasen PE, Haldsrud R, Kjeldsen SE, Rostrup M, Fadl Elmula FEM, Opdal MS, Høieggen A. Halvorsen LV, et al. J Am Heart Assoc. 2022 Sep 20;11(18):e025879. doi: 10.1161/JAHA.121.025879. Epub 2022 Sep 8. J Am Heart Assoc. 2022. PMID: 36073648 Free PMC article. - Quantitative Proteomics in Translational Absorption, Distribution, Metabolism, and Excretion and Precision Medicine.
Ahire D, Kruger L, Sharma S, Mettu VS, Basit A, Prasad B. Ahire D, et al. Pharmacol Rev. 2022 Jul;74(3):769-796. doi: 10.1124/pharmrev.121.000449. Pharmacol Rev. 2022. PMID: 35738681 Free PMC article. Review.
References
- Pharmacogenetics. 1991 Oct;1(1):26-32 - PubMed
- DNA Cell Biol. 1991 Oct;10(8):545-58 - PubMed
- Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):11825-9 - PubMed
- Pharmacogenetics. 1993 Dec;3(6):275-80 - PubMed
- Pharmacogenetics. 1994 Apr;4(2):47-57 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources